Vaccinex Shares Climb 18% on Keytruda Collaboration With Merck
17 September 2020 - 4:54PM
Dow Jones News
By Chris Wack
Vaccinex Inc. shares were up 18% to $6.25 after the company said
it has entered into a clinical collaboration agreement with Merck
& Co. to evaluate the combination of Vaccinex's investigational
SEMA4D inhibitor, pepinemab, and Merck's anti-PD-1 therapy,
Keytruda, in the treatment of patients with advanced, recurrent or
metastatic head and neck squamous cell carcinoma.
The planned clinical collaboration with pepinemab and Keytruda
(pembrolizumab) will consist of a dose escalation phase followed by
an expansion phase that will enroll up to 65 HNSCC patients
allocated to different levels of combined positive score of PD-L1
expression.
Combined positive score is a biomarker associated with benefit
in response to immunotherapy, and a major goal of this study is to
determine whether combination therapy can improve response in these
populations.
Vaccinex said key endpoints of the study include objective
response, progression free survival and overall survival.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 17, 2020 10:39 ET (14:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024